What is Summit Therapeutics's accounts payable?

Summit Therapeutics (SMMT) reported accounts payable of $6.8M in Q1 2026.

How has Summit Therapeutics's accounts payable changed year-over-year?

Summit Therapeutics's accounts payable increased by 1810.7% year-over-year, from $356K to $6.8M.

Summit Therapeutics SMMT Accounts Payable

Accounts Payable at other companies

Jazz PharmaceuticalsJAZZ

-$21.4M-212%

Gilead SciencesGILD

——

Other financials

Income statement

See full

Revenue-—

Operating income-$65.6M-81.2%

Net income-$189.4M-201%

EPS (diluted)-$0.24-167%

Balance sheet

See full

Cash & equivalents$8.2M+7.2%

Total debt$20.0M+211%

Total equity$545.9M+58.5%

Total assets$647.9M+68.8%

Cash flow

See full

Operating cash flow-$122.3M-99.9%

CapEx$245.0K-41.9%

Free cash flow-$122.5M-99.0%

Valuation

See full

Market cap$10.67B+3.3%

Enterprise value$10.68B+3.4%

Profitability

See full

Operating margin-268,266.8%-272,316pp

Net margin-271,685%-275,966pp

FCF margin-5,931.6%+4,730pp

Returns & leverage

See full

Return on equity-271%-1,725pp

Debt / equity0×0.0×

Current ratio7.4×-3.2×

Where this comes from

Reported directly by Summit Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayable.

The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Summit Therapeutics's accounts payable.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Summit Therapeutics's accounts payable?: Summit Therapeutics (SMMT) reported accounts payable of $6.8M in Q1 2026.
How has Summit Therapeutics's accounts payable changed year-over-year?: Summit Therapeutics's accounts payable increased by 1810.7% year-over-year, from $356K to $6.8M.